Fundraising Fox

Aclipse Therapeutics

Radnor, US · Founded 2017 · Delaware LLC

Aclipse Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying drug candidates for life-threatening neuromuscular and severe diseases, using genomic, proteomic, and biomarker data. Its lead programs include M107 for gastroparesis and M102 for amyotrophic lateral sclerosis (ALS).

BiotechMedical Devices

Founders & leadership

RK
Raymond K HouckNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$2.6M disclosed across 5 rounds · 2018–2020

▶$115KraisedAug 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raymond K HouckExecutive Officer, Director
Amount sold
$115K
First sale
Aug 2020
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25KraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raymond K HouckExecutive Officer, Director
Amount sold
$25K
First sale
Mar 2020
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200KraisedJun 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raymond K HouckExecutive Officer, Director
Amount sold
$200K
First sale
Jun 2019
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedMar 2019 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raymond K HouckExecutive Officer, Director
Amount sold
$1.2M
First sale
Jan 2018
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedMar 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Raymond K HouckExecutive Officer, Director
Amount sold
$1.1M
First sale
Mar 2019
Incorporated
Limited Liability Company, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Aclipse Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Aclipse Therapeutics do?
Aclipse Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying drug candidates for life-threatening neuromuscular and severe diseases, using genomic, proteomic, and biomarker data. Its lead programs include M107 for gastroparesis and M102 for amyotrophic lateral sclerosis (ALS).
How much funding has Aclipse Therapeutics raised?
Aclipse Therapeutics has disclosed $2.6M raised across 5 rounds.
Where is Aclipse Therapeutics headquartered?
Aclipse Therapeutics is headquartered in Radnor, US.